Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent.
about
Inorganic nanolayers: structure, preparation, and biomedical applicationsNanotechnology in drug delivery: the need for more cell culture based studies in screeningAntimycobacterial, antimicrobial, and biocompatibility properties of para-aminosalicylic acid with zinc layered hydroxide and Zn/Al layered double hydroxide nanocompositesDevelopment of drug delivery systems based on layered hydroxides for nanomedicine.Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications.Layered double hydroxide nanocomposite for drug delivery systems; bio-distribution, toxicity and drug activity enhancement.Characterization and in vitro studies of the anticancer effect of oxidized carbon nanotubes functionalized with betulinic acid.Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide.Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model.Acute oral toxicity and biodistribution study of zinc-aluminium-levodopa nanocomposite.In vitro wound healing potential and identification of bioactive compounds from Moringa oleifera Lam.Toxicity evaluation of zinc aluminium levodopa nanocomposite via oral route in repeated dose study.Aspergillus niger PA2: a novel strain for extracellular biotransformation of L-tyrosine into L-DOPA.Release of selected amino acids from zinc carriers.Development of a highly biocompatible antituberculosis nanodelivery formulation based on para-aminosalicylic acid-zinc layered hydroxide nanocomposites.Controlled release of organic-inorganic nanohybrid:cefadroxil intercalated Zn-Al-layered double hydroxide.Preparation of Tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system.Incorporation of Levodopa into Biopolymer Coatings Based on Carboxylated Carbon Nanotubes for pH-Dependent Sustained Release Drug Delivery.Sustained Release and Cytotoxicity Evaluation of Carbon Nanotube-Mediated Drug Delivery System for Betulinic AcidA Review on Characterizations and Biocompatibility of Functionalized Carbon Nanotubes in Drug Delivery Design
P2860
Q26781178-43549C20-45A5-40E9-8106-6FEF6CCC58F7Q28390779-60E383E0-B7CB-4F7D-9FF8-98A2A0C895F6Q34003943-7B9234E7-964A-4C47-8388-639B861C7594Q35164120-51BC82E3-C1A0-496A-A02E-19327BFA9C9FQ37420871-459515A5-2B35-431B-923F-E06FF706C9EDQ38245232-6C856CFB-7210-4501-ADDA-A4770E4D79C2Q38937401-627307A5-5BBF-404F-AAB8-22922B8012B2Q38942654-99B45620-21EE-4E43-A4AF-4672732224B4Q38945902-0DFFC36B-45D4-4176-ACA3-1E11CC14C61FQ39005352-A05F034B-D98A-4072-AD0D-30E2B564D769Q39223684-6600034F-CBB9-45D9-85A8-85452CF1C004Q39278825-7086076F-0FDB-48C2-86CB-25529388661CQ40412017-14D3C06F-34A1-4E63-93E7-4939A25B6FE8Q46429067-E382A844-4519-46B5-85FF-E3D43D66A2B3Q53084299-F16C42BC-4565-40E0-8283-5E362F6527DFQ53495106-62F2580A-0ECE-498E-91D1-0A156DE7BD1EQ55206230-BA4EBF76-C38A-40C6-B74E-A1DEDB0C9160Q55451914-305B0428-5017-454A-9F0A-A529E28D6AB3Q55667870-753D8988-1FFC-4559-B9E1-6117877B6D50Q59059363-93175EC9-638B-4788-ACE2-BF2FCEBD86C5Q59059498-523BBC07-A33F-4BC5-A700-024F4C5F91C9
P2860
Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Development of a controlled-re ...... levodopa as the active agent.
@en
Development of a controlled-re ...... levodopa as the active agent.
@nl
type
label
Development of a controlled-re ...... levodopa as the active agent.
@en
Development of a controlled-re ...... levodopa as the active agent.
@nl
prefLabel
Development of a controlled-re ...... levodopa as the active agent.
@en
Development of a controlled-re ...... levodopa as the active agent.
@nl
P2093
P2860
P356
P1476
Development of a controlled-re ...... g levodopa as the active agent
@en
P2093
Aminu Umar Kura
Palanisamy Arulselvan
Samer Hasan Hussein Al Ali
Sharida Fakurazi
P2860
P304
P356
10.2147/IJN.S39740
P407
P577
2013-03-16T00:00:00Z